Journal of Clinical Oncology
Articles in this Issue
Efficacy of trastuzumab and trastuzumab adjunct chemotherapy HER2 amplified colorectal cancer: A systematic review and meta-analysis.
e15596 Background: Colorectal Cancer (CRC) is a major global health burden, accounting for an estimated 10% of all tumour cases and reigning as the third...
Comparative impact of metronomic therapy (methotrexate and celecoxib) and cisplatin-based radiochemotherapy on health-related quality of life in tracheostomized head and neck cancer patients: A comparative analysis.
e18002 Background: Tracheostomy is a common intervention for managing airway obstruction in advanced head and neck squamous cell carcinoma (H&N SCC),...
Real-world experience with dose-adjusted EPOCH-R in diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma: A multicenter analysis from Turkey.
e19062 Background: Dose-adjusted EPOCH-R (DA-EPOCH-R) has demonstrated efficacy in aggressive B-cell lymphomas, yet comprehensive real-world data from mul...
Imlunestrant with or without abemaciclib in advanced breast cancer (ABC): Safety analyses from the phase III EMBER-3 trial.
1060 Background: Imlunestrant is a next-generation, brain-penetrant, oral SERD. The EMBER-3 trial (NCT04975308) in patients with ER+, HER2- ABC and diseas...
Development of a novel nomogram to predict clinically significant prostate cancer using ExoDx urinary biomarker and multiparametric MRI.
e17158 Background: The ExoDx urinary biomarker test has been validated for the investigation elevated prostate specific antigen (PSA) levels. The performa...
Sequential or up-front triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma (AIO-MONTBLANC): Safety interim analysis.
4122 Background: The combination of immune checkpoint inhibitors (ICI) durvalumab (durva) and tremelimumab (treme) has been approved for first-line (1L) t...
The WinPro trial: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer.
513 Background: Preclinical evidence has shown that progesterone is a tumour suppressor in estrogen receptor positive (ER+) breast cancer. Prometrium is b...
Association between Geriatric 8 frailty, guideline treatment, treatment adherence, and overall survival in older patients with cancer (PROGNOSIS-G8).
1623 Background: Frailty is frequent among older adults with cancer and may affect oncologic treatment tolerance. Frailty screening, with tools such as th...
Progression-free survival (PFS) assessment by blinded independent central review (BICR) versus local investigator (LI) in metastatic melanoma (MM) randomized controlled trials (RCT): A systematic review and meta-analysis.
9545 Background: Although BICR may reduce assessment variability, it introduces additional financial and logistical burdens to trial operations. This stud...
The impact of breast cancer treatment on young women’s body image and sexual health.
11134 Background: In 2023 MSKCC launched the Young Women with Breast Cancer Program (YWBCP) to provide comprehensive care, education, and research studies...
Total neoadjuvant therapy with induction immunochemotherapy and chemoradiotherapy followed by surgery for locally advanced esophageal squamous cell carcinoma (TNT-ESCC).
TPS4213 Background: Locally advanced esophageal squamous cell carcinoma (ESCC) is indicated for multi-modalities treatment strategies, including a neoadju...
Prognostic role of pre-treatment eosinophilia in NSCLC patients undergoing immune checkpoint inhibitor therapy: A meta-analysis.
e20620 Background: Precision management of non-small cell lung cancer (NSCLC) requires biomarkers to predict immunotherapy response. Though eosinophilia c...
Hepatitis B virus reactivation in hepatocellular carcinoma patients undergoing immune checkpoint inhibitor and concurrent antiviral prophylaxis agents: A prospective observational study.
4127 Background: Immune checkpoint inhibitors (ICIs) have been recommended for the treatment of advanced hepatocellular carcinoma (HCC). However, due to t...
Racial disparities in molecularly targeted trials of tyrosine kinase inhibitors (TKI) for the perioperative management of oncogene-driven non-small cell lung cancer (NSCLC): A systematic review.
e20015 Background: The treatment of non-small cell lung cancer (NSCLC) has experienced a significant shift with the introduction of targeted therapies. Wh...
The association between Gleason grade group, PSA levels, and prostatectomy outcomes for the optimized treatment of prostate cancer patients.
e17141 Background: Radical prostatectomy is a common approach for managing localized prostate cancer (PCa). Positive surgical margins (PSMs), upstaging or...
First-line envafolimab in combination with recombinant human endostatin and chemotherapy for advanced squamous non-small cell lung cancer: Updated results from a prospective, single-arm, multicenter phase II study.
8573 Background: Immunotherapy combined with chemotherapy has been established as the standard first-line treatment for patients with advanced squamous NS...
Real-world outcomes of patients with multiple myeloma treated with T-cell engagers compared to those treated on clinical trials.
e19519 Background: T-cell engagers (TCE) have altered the therapeutic landscape, demonstrating response rates of 60-70% for patients with relapsed/refract...
Phase I trial of personalized AI-identified TCR-transduced T cell therapy in advanced solid tumors.
2535 Background: TCR-T cell therapy shows promise in treating solid tumors but is limited by the need for personalized TCR identification. We developed TC...
Comprehensive clinicopathologic analysis and management approaches for metaplastic breast cancer: A retrospective, single institution study.
e13176 Background: Metaplastic breast cancer (MpBC) is a rare and aggressive subtype of breast cancer characterized by its heterogeneous histology and poo...
Black patients with cutaneous T-cell lymphoma (CTCL) and their likelihood to receive novel agents: A retrospective cohort analysis.
e13822 Background: Black patients with cutaneous T-cell lymphoma (CTCL) have increased risk of mortality compared to other racial groups. The introduction...
Cancer provider experiences with telehealth.
e13888 Background: Since the COVID-19 pandemic, there has been a surge in the use of telehealth in cancer care. However, there is limited data on cancer c...
Addressing disparities by implementing a supportive care program in oncology.
11082 Background: Financial toxicity, transportation needs, and emotional strain are known barriers to receipt of cancer care and cause for disparities in...
Correlation of clinical benefit from immune checkpoints and baseline radiomic signature in inoperable NSCLC without activating mutations.
e20571 Background: Checkpoint inhibitors (ICI) are an important part of the NSCLC treatment algorithm. Existing criteria for ICI efficacy prognostication...
Phase 1/2 study of tiragolumab and atezolizumab in patients with relapsed or refractory SMARCB1- or SMARCA4-deficient tumors: PEPN2121.
TPS2695 Background: The SMARCB1/A4 gene products are core subunits of the SWItch/Sucrose Non Fermentable (SWI/SNF) chromatin remodeling complex. Tumors wi...
Updated trends in second primary malignancy in patients with renal cell carcinoma: A retrospective population-based analysis.
e16546 Background: Survival outcomes for patients with renal cell carcinoma (RCC) have improved in recent years. However, the risk of developing second pr...